{
  "_id": "0cad32e309269c8a010503a0538815c05a43486c7776acc194006b2d25d05756",
  "feed": "wall-street-journal",
  "title": "What Biotech ETFs Might Be Right for Your Portfolio? A look at the offerings in what has become a hot sector this summer",
  "text": "<p>Here are some of the most prominent biotechnology ETFs and some key facts:</p><p>iShares Biotechnology ETF (IBB): Mostly large-cap companies</p><p>* The market-cap-weighted index is up 9.6% this quarter through Thursday.</p><p>* Top holdings as of Aug. 12 include Vertex Pharmaceuticals Inc., Gilead Sciences Inc., Amgen Inc. and Regeneron Pharmaceuticals Inc.</p><p>* Market value: $8.53 billion</p><p>* Expense ratio: 0.44%</p><p>SPDR S&amp;P Biotech ETF (XBI): Mostly small and midcap companies</p><p>* The equal-weighted index is up 19.4% this quarter.</p><p>* Top holdings as of Aug. 17 include Global Blood Therapeutics Inc., Karuna Therapeutics Inc. and ChemoCentryx Inc.</p><p>* Market value: $8.46 billion</p><p>* Expense ratio: 0.35%</p><p>ARK Genomic Revolution ETF (ARKG): Mostly small and midcap companies</p><p>* The (methodology undisclosed) index is up nearly 21% this quarter.</p><p>* Top holdings as of Aug. 17 include Exact Sciences Corp., Signify Health Inc. Class A, Ionis Pharmaceuticals Inc.</p><p>* Market value: $3.09 billion</p><p>* Expense ratio: 0.75%</p><p>First Trust NYSE Arca Biotechnology Index Fund (FBT): Mostly large and midcap companies</p><p>* The equal-weighted index is up 6.4% this quarter.</p><p>* Top holdings as of Aug. 17 include Alnylam Pharmaceuticals Inc., Sarepta Therapeutics Inc., Agios Pharmaceuticals Inc. and FibroGen Inc.</p><p>* Market value: $1.43 billion</p><p>* Expense ratio: 0.55%</p><p>You will notice there are different ways of making up an ETF. Market-cap-weighted ETFs, which hold more of a given constituent company the larger that firm is by market value, generally offer greater exposure to large companies, while equal-weighted ETFs often focus on smaller firms. Most biotech companies are unprofitable as they pursue drug development and commercialization.</p><p>\"If you're going to play biotech, play biotech more from the market-cap-weighted versus the equal-weighted,\" says Jon Maier, chief investment officer at Global X ETFs.</p><p>SHARE YOUR THOUGHTS</p><p>Which biotech ETFs are you most interested in right now? Join the conversation below.</p><p>His fund manages the Global X Genomics &amp; Biotechnology ETF, which is up 22% this quarter. This market-cap-weighted ETF primarily has midcap and small companies with its top holdings as of Aug. 17, including Exact Sciences Corp., Signify Health Inc., Ionis Pharmaceuticals Inc. and Teladoc Health Inc.</p><p>Biotechs are also a sizable part of the Russell 2000 index of small-cap companies, though the index provider recently cut dozens of biotechs from that index as part of a regular culling of laggards.</p><p>The Russell 2000 now includes 189 biotech stocks, according to Bank of America U.S. equity strategist Jill Carey Hall. The broader small-cap index is up 12.3% in the past three months, while its biotech index is up 37.8% in the same period.</p><p>\"The field has gotten more competitive, but the pace of innovation has continued to accelerate, and this is a sector that can have huge implications,\" said Dr. Brian Abrahams, managing director and head of biotechnology equity research at RBC Capital Markets.</p><p>Write to Pia Singh at Pia.Singh@wsj.com</p><p>What Biotech ETFs Might Be Right for Your Portfolio?</p>",
  "published": "2022-08-19T09:30:00.000Z",
  "tags": [
    {
      "id": "US0311621009",
      "nexusId": "10036019",
      "name": "Amgen Inc.",
      "confidence": 0.7,
      "offsets": [
        {
          "start": 297,
          "end": 307
        }
      ],
      "weightsV2": {
        "weight": 0.6663995,
        "baseWeight": 1.0,
        "expansionWeight": 0.0,
        "ontologyWeight": -0.4311999,
        "tagPositionWeight": 0.09759939,
        "titleWeight": 0.0
      },
      "typeRank": 4
    }
  ]
}